Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

NCT05261438 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-03-02

No results posted yet for this study

Summary

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Conditions

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-05-01
Completion
2021-09-15

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05261438 on ClinicalTrials.gov